← Back to headlines

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

This story is reported by The New England Journal of Medicine. Read what other outlets are saying below, then open the original report for full details.

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma · NabkaNews